The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

If not controlled with the above measures, your eczema might require prescription treatments like corticosteroids or even ...

An analysis of three phase 3 trials reported relief with upadacitinib through 76 weeks in adolescents with AD.

Explore innovative nutritional and microbial strategies for effectively treating acne, alopecia, and atopic dermatitis.

Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

A live and archived webcast of the fireside chats and presentations will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.